JNJ - Week In Review: Adagene Forms $2.5-Billion Four-Drug Partnership With Sanofi
- Suzhou antibody company Adagene will apply its masking technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion.
- Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentially worth more than $1 billion. The drug rights are worth up to $930 million, while Huadong will also purchase 35% of Heidelberg for $118 million.
- AnHeart Therapeutics (Hangzhou) and Suzhou Innovent said their partnered ROS1 tyrosine kinase inhibitor received China Breakthrough Therapy Designation.
For further details see:
Week In Review: Adagene Forms $2.5-Billion, Four-Drug Partnership With Sanofi